Evidence map›Paper›PMID 38283356›Full record

ArticleFrontiers in immunology2023

Effects of polyphenolic maqui (

Tamara Ortiz-Cerda, Federico Argüelles-Arias, Laura Macías-García, Victoria Vázquez-Román, Gladys Tapia, Kangzhe Xie, María Desirée García-García, Manuel Merinero, Josefa-María García-Montes, Ana Alcudia and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Experimental and therapeutic medicine · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Protective Mechanism ofNutrients · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Tamara Ortiz-CerdaDepartamento de Citología e Histología Normal y Patológica, Facultad de medicina, Universidad de Sevilla, Seville, Spain.
Federico Argüelles-AriasDepartamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Seville, Spain.
Laura Macías-GarcíaDepartamento de Citología e Histología Normal y Patológica, Facultad de medicina, Universidad de Sevilla, Seville, Spain.
Victoria Vázquez-RománDepartamento de Citología e Histología Normal y Patológica, Facultad de medicina, Universidad de Sevilla, Seville, Spain.
Gladys TapiaMolecular and Clinical Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Kangzhe XieRedox Biology Group, The Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
María Desirée García-GarcíaDepartment of Gastroenterology, University Hospital Virgen Macarena, Seville, Spain.
Manuel MerineroDepartamento de Citología e Histología Normal y Patológica, Facultad de medicina, Universidad de Sevilla, Seville, Spain.
Josefa-María García-MontesDepartamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Seville, Spain.
Ana AlcudiaDepartamento de Química Orgánica y Farmacéutica, Universidad de Sevilla, Seville, Spain.
Paul K WittingRedox Biology Group, The Charles Perkins Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Manuel De-MiguelDepartamento de Citología e Histología Normal y Patológica, Facultad de medicina, Universidad de Sevilla, Seville, Spain.
Universidad de Sevilla · ESUniversity of Sydney · AUHospital Universitario Virgen Macarena · ESUniversity of Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Crohn's disease (CD) involves activation of mast cells (MC) and NF-кB in parallel with the PPAR-α/NLRP3 inflammasome/IL-1β pathway in the inflamed colon. Whether polyphenols from maqui ( Methods: Maqui extract was administered via orogastric route to mice after (post-Treatment group) or prior (pre-Treatment group) to TNBS-induction. Colon pathology was characterized by histoarchitectural imaging, disease activity index (DAI), and assessing NF-кB, p-NF-кB, PPAR-α/NLRP3 expression and IL-1β levels. Results: Compared to mice treated with TNBS alone administration of anthocyanin-rich maqui extract improved the DAI, colon histoarchitecture and reduced both colon wet-weight and transmural inflammation. Induction with TNBS significantly increased colonic NLPR3 inflammasome activation, while co-treatment with maqui extract (either post- or pre-Treatment) significantly downregulated NLRP3, ASC and caspase-1 levels, which manifested as reduced colonic IL-1β levels. Supplemented maqui extract marginally diminished NF-кB activity in epithelial cells but reached statistical significance in immune cells (as judged by decreased NF-кB phosphorylation). PPAR-α signaling was largely unaffected by Maqui whereas MC infiltration into the colon mucosa and submucosa decreased and their level of degranulation was suppressed. Conclusion: These outcomes show the post- and pre- Treatment effect of a polyphenolic extract rich in anthocyanins from maqui the acute phase of TNBS- induced CD-like colitis is linked to suppression of the NLRP3 inflammasome and reduced MC responses. These data indicate that maqui extract represents a potential nutraceutical for the treatment of inflammatory bowel disease (IBD).

Indexed as

AnthocyaninsColitisCrohn DiseaseAnimalsInflammasomesMast CellsMiceNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinPeroxisome Proliferator-Activated ReceptorsAnthocyaninsInflammasomesNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinPeroxisome Proliferator-Activated ReceptorsanthocyaninsCrohn’s diseaseinterleukin 1βmaquimast cellsNLRP3 inflammasomepolyphenols

Identifiers

PMID38283356
PMCPMC10811055
OpenAlexW4390790204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.